FRTX NASDAQ
Fresh Tracks Therapeutics, Inc.
1W: +3.3%
1M: +1.1%
3M: +30.6%
1Y: +4.4%
3Y: -90.5%
5Y: -99.3%
$0.94
Last traded 2025-02-28 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$8M
+15.3% ▲
5Y CAGR: +37.6%
Gross Profit
$8M
+212.8% ▲
5Y CAGR: +112.2%
Operating Income
-$6M
+70.5% ▲
Net Income
-$6M
+72.4% ▲
EPS (Diluted)
$-0.96
+87.0% ▲
EBITDA
-$6M
+73.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $8M | $2M | $404K | $7M | $8M |
| YoY Growth | +388.1% | -77.0% | -77.8% | +1618.6% | +15.3% |
| Cost of Revenue | $20M | $11M | $28M | $14M | $0 |
| Gross Profit | -$12M | -$9M | -$28M | -$7M | $8M |
| Gross Margin | -155.3% | -515.6% | -6887.9% | -102.3% | 100.0% |
| R&D Expenses | $20M | $11M | $28M | $14M | $3M |
| SG&A Expenses | $12M | $12M | $12M | $14M | $11M |
| Operating Expenses | $32M | $23M | $41M | $28M | $14M |
| Operating Income | -$24M | -$21M | -$40M | -$22M | -$6M |
| Operating Margin | -309.1% | -1151.3% | -9961.4% | -310.2% | -79.4% |
| Interest Expense | $2M | $0 | $69K | $9K | $5K |
| Income Before Tax | -$24M | -$21M | -$39M | -$21M | -$6M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$26M | -$21M | -$40M | -$21M | -$6M |
| Net Margin | -327.7% | -1147.3% | -9782.4% | -297.6% | -71.1% |
| EPS (Diluted) | $-386.21 | $-38.37 | $-22.14 | $-7.36 | $-0.96 |
| EBITDA | -$22M | -$21M | -$39M | -$21M | -$6M |
| Shares Outstanding | 67178 | 544759 | 2M | 3M | 6M |